Modulators of eukaryotic initiation factor 2B, compositions and methods
AssigneeDenali Therapeutics Inc.
InventorsRobert A. Craig, II, Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Brian M. Fox, Christopher R. H. Hale, Katrina W. Lexa, Maksim Osipov, Travis Remarchuk, Zachary K. Sweeney
Life of this patent
Estimating the term…
Abstract
The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or prodrug thereof, and methods of making and using thereof.
Claims30
A compound or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, selected from the group consisting of:
A compound having the structure:
- or a pharmaceutically acceptable salt thereof.
A compound having the structure:
- or a pharmaceutically acceptable salt thereof.
A compound having the structure:
- or a pharmaceutically acceptable salt thereof.
A compound having the structure:
- or a pharmaceutically acceptable salt thereof.
A compound having the structure:
- or a pharmaceutically acceptable salt thereof.
A compound having the structure:
- or a pharmaceutically acceptable salt thereof.
A compound having the structure:
- or a pharmaceutically acceptable salt thereof.
A compound having the structure:
- or a pharmaceutically acceptable salt thereof.
A compound having the structure:
- or a pharmaceutically acceptable salt thereof.
A compound having the structure:
- or a pharmaceutically acceptable salt thereof.
A compound having the structure:
- or a pharmaceutically acceptable salt thereof.
A compound having the structure:
- or a pharmaceutically acceptable salt thereof.
A compound having the structure:
- or a pharmaceutically acceptable salt thereof.
A compound having the structure:
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.